Regulation of inflammation in cancer by eicosanoids

Mantovani, 2009, Cancer: inflaming metastasis, Nature, 457, 36, 10.1038/457036b Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Balkwill, 2001, Inflammation and cancer: back to Virchow?, Lancet, 357, 539, 10.1016/S0140-6736(00)04046-0 Balkwill, 2010, Cancer and inflammation: implications for pharmacology and therapeutics, Clin Pharmacol Ther, 87, 401, 10.1038/clpt.2009.312 Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Vakkila, 2004, Inflammation and necrosis promote tumour growth, Nat Rev Immunol, 4, 641, 10.1038/nri1415 Ekbom, 1990, Ulcerative colitis and colorectal cancer. A population-based study, N Engl J Med, 323, 1228, 10.1056/NEJM199011013231802 Kulaylat, 2010, Ulcerative colitis and cancer, J Surg Oncol, 101, 706, 10.1002/jso.21505 Harris, 2003, Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative, Cancer Res, 63, 6096 Harris, 2009, Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung, Inflammopharmacology, 17, 55, 10.1007/s10787-009-8049-8 Wang, 2010, Eicosanoids and cancer, Nat Rev Cancer, 10, 181, 10.1038/nrc2809 Wallace, 2002, Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases, and lipoxygenases—as an adjunct in cancer therapy, Integr Cancer Ther, 1, 7 McMillan, 2000, Changes in micronutrient concentrations following anti-inflammatory treatment in patients with gastrointestinal cancer, Nutrition, 16, 425, 10.1016/S0899-9007(00)00270-7 Barber, 1999, Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer, Clin Sci (Lond), 96, 83, 10.1042/CS19980185 Lawrence, 2007, Inflammation and cancer: a failure of resolution?, Trends Pharmacol Sci, 28, 162, 10.1016/j.tips.2007.02.003 Zeldin, 2001, Epoxygenase pathways of arachidonic acid metabolism, J Biol Chem, 276, 36059, 10.1074/jbc.R100030200 2009 Imig, 2009, Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases, Nat Rev Drug Discov, 8, 794, 10.1038/nrd2875 Krishnamoorthy, 2008, Eicosanoids in tumor progression and metastasis, Subcell Biochem, 49, 145, 10.1007/978-1-4020-8831-5_6 Panigrahy, 2010, Cytochrome P450-derived eicosanoids: the neglected pathway in cancer, Cancer Metastasis Rev, 29, 723, 10.1007/s10555-010-9264-x Roman, 2002, P-450 metabolites of arachidonic acid in the control of cardiovascular function, Physiol Rev, 82, 131, 10.1152/physrev.00021.2001 Fleming, 2007, Epoxyeicosatrienoic acids, cell signaling and angiogenesis, Prostaglandins Other Lipid Mediat, 82, 60, 10.1016/j.prostaglandins.2006.05.003 Spector, 2007, Action of epoxyeicosatrienoic acids on cellular function, Am J Physiol Cell Physiol, 292, C996, 10.1152/ajpcell.00402.2006 Rainsford, 2007, Anti-inflammatory drugs in the 21st century, Subcell Biochem, 42, 3, 10.1007/1-4020-5688-5_1 Vane, 1971, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nat New Biol, 231, 232, 10.1038/newbio231232a0 Vane, 1982, Adventures and excursions in bioassay: the stepping stones to prostacyclin, 181 Samuelsson, 1982, From studies of biochemical mechanisms to novel biological mediators: prostaglandin endoperoxides, thromboxanes and leukotrienes, 153 Serhan, 2011, The resolution of inflammation: the devil in the flask and in the details, FASEB J, 25, 1441, 10.1096/fj.11-0502ufm Serhan, 1984, Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes, Proc Natl Acad Sci USA, 81, 5335, 10.1073/pnas.81.17.5335 Serhan, 2000, Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing, J Exp Med, 192, 1197, 10.1084/jem.192.8.1197 Serhan, 2002, Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals, J Exp Med, 196, 1025, 10.1084/jem.20020760 Serhan, 2011, Novel anti-inflammatory—pro-resolving mediators and their receptors, Curr Top Med Chem, 11, 629, 10.2174/1568026611109060629 Kasuga, 2008, Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution, J Immunol, 181, 8677, 10.4049/jimmunol.181.12.8677 Wymann, 2008, Lipid signalling in disease, Nat Rev Mol Cell Biol, 9, 162, 10.1038/nrm2335 Gilroy, 2004, A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation, FASEB J, 18, 489, 10.1096/fj.03-0837com Agarwal, 2009, Eicosanoids in inflammation and cancer: the role of COX-2, Expert Rev Clin Immunol, 5, 145, 10.1586/1744666X.5.2.145 Mantovani, 2005, Cancer: inflammation by remote control, Nature, 435, 752, 10.1038/435752a Coussens, 2000, MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis, Cell, 103, 481, 10.1016/S0092-8674(00)00139-2 Panigrahy, 2002, PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis, J Clin Invest, 110, 923, 10.1172/JCI0215634 Panigrahy, 2008, PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition, Proc Natl Acad Sci USA, 105, 985, 10.1073/pnas.0711281105 Panigrahy, 2008, PPARs: a double-edged sword in cancer therapy?, PPAR Res, 350351 Kieran, 2005, A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer, J Pediatr Hematol Oncol, 27, 573, 10.1097/01.mph.0000183863.10792.d4 Panigrahy, 2010, Inhibition of tumor angiogenesis by oral etoposide, Exp Ther Med, 1, 739, 10.3892/etm.2010.127 Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Orimo, 2005, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, Cell, 121, 335, 10.1016/j.cell.2005.02.034 Joyce, 2009, Microenvironmental regulation of metastasis, Nat Rev Cancer, 9, 239, 10.1038/nrc2618 Mahida, 2000, The key role of macrophages in the immunopathogenesis of inflammatory bowel disease, Inflamm Bowel Dis, 6, 21, 10.1002/ibd.3780060105 Solinas, 2010, Inflammation-mediated promotion of invasion and metastasis, Cancer Metastasis Rev, 29, 243, 10.1007/s10555-010-9227-2 Dinarello, 2006, The paradox of pro-inflammatory cytokines in cancer, Cancer Metastasis Rev, 25, 307, 10.1007/s10555-006-9000-8 Barleon, 1996, Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1, Blood, 87, 3336, 10.1182/blood.V87.8.3336.bloodjournal8783336 Kim, 2009, Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis, Nature, 457, 102, 10.1038/nature07623 Noonan, 2008, Inflammation, inflammatory cells and angiogenesis: decisions and indecisions, Cancer Metastasis Rev, 27, 31, 10.1007/s10555-007-9108-5 Clevers, 2004, At the crossroads of inflammation and cancer, Cell, 118, 671, 10.1016/j.cell.2004.09.005 Aggarwal, 2006, Inflammation and cancer: how hot is the link?, Biochem Pharmacol, 72, 1605, 10.1016/j.bcp.2006.06.029 Zhang, 2003, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N Engl J Med, 348, 203, 10.1056/NEJMoa020177 Kaipainen, 2007, PPARalpha deficiency in inflammatory cells suppresses tumor growth, PLoS One, 2, e260, 10.1371/journal.pone.0000260 Ono, 2008, Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy, Cancer Sci, 99, 1501, 10.1111/j.1349-7006.2008.00853.x Freedman, 2007, Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer, Clin Cancer Res, 13, 5736, 10.1158/1078-0432.CCR-07-0583 Mal, 2011, Ultra-pressure liquid chromatography/tandem mass spectrometry targeted profiling of arachidonic acid and eicosanoids in human colorectal cancer, Rapid Commun Mass Spectrom, 25, 755, 10.1002/rcm.4926 Smyth, 2009, Prostanoids in health and disease, J Lipid Res, 50, S423, 10.1194/jlr.R800094-JLR200 Wang, 2007, Cyclooxygenases, prostanoids, and tumor progression, Cancer Metastasis Rev, 26, 525, 10.1007/s10555-007-9096-5 Dubois, 1998, Cyclooxygenase in biology and disease, FASEB J, 12, 1063, 10.1096/fasebj.12.12.1063 Eberhart, 1994, Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas, Gastroenterology, 107, 1183, 10.1016/0016-5085(94)90246-1 Wang, 2010, The role of COX-2 in intestinal inflammation and colorectal cancer, Oncogene, 29, 781, 10.1038/onc.2009.421 Howe, 2007, Inflammation and breast cancer cyclooxygenase/prostaglandin signaling and breast cancer, Breast Cancer Res, 9, 210, 10.1186/bcr1678 Rajakariar, 2006, COX-2 in inflammation and resolution, Mol Interv, 6, 199, 10.1124/mi.6.4.6 Ricciotti, 2011, Prostaglandins and inflammation, Arterioscler Thromb Vasc Biol, 31, 986, 10.1161/ATVBAHA.110.207449 Rigas, 1993, Altered eicosanoid levels in human colon cancer, J Lab Clin Med, 122, 518 Wang, 2004, Cyclooxygenase-2: a potential target in breast cancer, Semin Oncol, 31, 64, 10.1053/j.seminoncol.2004.01.008 McLemore, 1988, Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients, Cancer Res, 48, 3140 Hambek, 2007, Inverse correlation between serum PGE2 and T classification in head and neck cancer, Head Neck, 29, 244, 10.1002/hed.20503 Wang, 2006, Prostaglandins and cancer, Gut, 55, 115, 10.1136/gut.2004.047100 Cha, 2007, NSAIDs and cancer prevention: targets downstream of COX-2, Annu Rev Med, 58, 239, 10.1146/annurev.med.57.121304.131253 Wang, 2004, Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta, Cancer Cell, 6, 285, 10.1016/j.ccr.2004.08.011 Nakanishi, 2008, Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis, Cancer Res, 68, 3251, 10.1158/0008-5472.CAN-07-6100 Meyer, 2004, Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2, Carcinogenesis, 25, 1517, 10.1093/carcin/bgh150 Walker, 2004, Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis, Immunology, 111, 298, 10.1111/j.1365-2567.2004.01810.x Rodriguez-Vita, 2010, The resolution of inflammation and cancer, Cytokine Growth Factor Rev, 21, 61, 10.1016/j.cytogfr.2009.11.006 Voronov, 2003, IL-1 is required for tumor invasiveness and angiogenesis, Proc Natl Acad Sci USA, 100, 2645, 10.1073/pnas.0437939100 Saijo, 2002, Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor–stromal interaction, J Immunol, 169, 469, 10.4049/jimmunol.169.1.469 Bunt, 2006, Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression, J Immunol, 176, 284, 10.4049/jimmunol.176.1.284 Sinha, 2007, Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells, Cancer Res, 67, 4507, 10.1158/0008-5472.CAN-06-4174 Backlund, 2005, 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer, J Biol Chem, 280, 3217, 10.1074/jbc.M411221200 Wolf, 2006, 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer, Cancer Res, 66, 7818, 10.1158/0008-5472.CAN-05-4368 Hughes, 2008, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer, Cancer Prev Res (Phila), 1, 241, 10.1158/1940-6207.CAPR-08-0055 Thiel, 2009, 15-Hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer, Clin Cancer Res, 15, 4572, 10.1158/1078-0432.CCR-08-2518 Tseng-Rogenski, 2010, Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression, Am J Pathol, 176, 1462, 10.2353/ajpath.2010.090875 Tatsuwaki, 2010, Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma, Cancer Sci, 101, 550, 10.1111/j.1349-7006.2009.01390.x Wu, 2010, Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms, Cancer Lett, 295, 7, 10.1016/j.canlet.2010.03.015 Watanabe, 1999, Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis, Cancer Res, 59, 5093 Shoji, 2005, Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis, Carcinogenesis, 26, 2116, 10.1093/carcin/bgi193 Shoji, 2004, Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development, Gut, 53, 1151, 10.1136/gut.2003.028787 Mutoh, 2002, Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis, Cancer Res, 62, 28 Kawamori, 2001, Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development, Carcinogenesis, 22, 2001, 10.1093/carcin/22.12.2001 Piazuelo, 2006, Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus, Prostaglandins Other Lipid Mediat, 81, 150, 10.1016/j.prostaglandins.2006.09.002 Yang, 2006, Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism, Cancer Res, 66, 9665, 10.1158/0008-5472.CAN-06-1271 Takahashi, 2008, Soluble EP2 neutralizes prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth, Mol Cancer Ther, 7, 2807, 10.1158/1535-7163.MCT-08-0153 George Paul, 2010, Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi's sarcoma-associated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen, Cancer Res, 70, 3697, 10.1158/0008-5472.CAN-09-3934 Park, 2007, Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice, Cancer Res, 67, 881, 10.1158/0008-5472.CAN-05-3767 Zamuner, 2005, Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2, Am J Pathol, 167, 1293, 10.1016/S0002-9440(10)61216-3 Vong, 2010, A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis, Proc Natl Acad Sci USA, 107, 12023, 10.1073/pnas.1004982107 Oba, 2009, A selective cyclooxygenase-2 inhibitor prevents inflammation-related squamous cell carcinogenesis of the forestomach via duodenogastric reflux in rats, Cancer, 115, 454, 10.1002/cncr.23990 Gupta, 2004, Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model, Cancer Res, 64, 3334, 10.1158/0008-5472.CAN-03-2422 Kiguchi, 2007, Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice, Mol Cancer Ther, 6, 1709, 10.1158/1535-7163.MCT-07-0015 Steinbach, 2000, The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis, N Engl J Med, 342, 1946, 10.1056/NEJM200006293422603 Bresalier, 2005, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 352, 1092, 10.1056/NEJMoa050493 Solomon, 2005, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl J Med, 352, 1071, 10.1056/NEJMoa050405 Baron, 2006, A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas, Gastroenterology, 131, 1674, 10.1053/j.gastro.2006.08.079 Funk, 2007, COX-2 inhibitors and cardiovascular risk, J Cardiovasc Pharmacol, 50, 470, 10.1097/FJC.0b013e318157f72d Cuzick, 2009, Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement, Lancet Oncol, 10, 501, 10.1016/S1470-2045(09)70035-X Rothwell, 2010, Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, 376, 1741, 10.1016/S0140-6736(10)61543-7 Claria, 1996, Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation, Mol Med, 2, 583, 10.1007/BF03401642 Pidgeon, 2007, Lipoxygenase metabolism: roles in tumor progression and survival, Cancer Metastasis Rev, 26, 503, 10.1007/s10555-007-9098-3 Chen, 2004, Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis, Clin Cancer Res, 10, 6703, 10.1158/1078-0432.CCR-04-0838 Ye, 2004, Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking, Toxicology, 203, 179, 10.1016/j.tox.2004.06.004 Nie, 1998, Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth, Cancer Res, 58, 4047 Kerjaschki, 2011, Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse, J Clin Invest, 121, 2000, 10.1172/JCI44751 Gilbert, 2011, The structure of human 5-lipoxygenase, Science, 331, 217, 10.1126/science.1197203 Rioux, 1998, Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents, Carcinogenesis, 19, 1393, 10.1093/carcin/19.8.1393 Gunning, 2002, Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice, Cancer Res, 62, 4199 Mobius, 2008, Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma, Anticancer Res, 28, 873 Ye, 2005, Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke, Carcinogenesis, 26, 827, 10.1093/carcin/bgi012 Fegn, 2009, Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2, J Laryngol Otol, 123, 880, 10.1017/S0022215109004617 Wenger, 2002, Effects of celebrex and zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters, Clin Exp Metastasis, 19, 681, 10.1023/A:1021387826867 Menna, 2010, Lipoxygenase inhibitors for cancer prevention: promises and risks, Curr Pharm Des, 16, 725, 10.2174/138161210790883822 Tavolari, 2008, Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade, Carcinogenesis, 29, 371, 10.1093/carcin/bgm265 Guo, 2011, Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival, Cancer Chemother Pharmacol, 10.1007/s00280-011-1595-y Claesson, 2009, On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma, Prostaglandins Other Lipid Mediat, 89, 120, 10.1016/j.prostaglandins.2008.12.003 Ikawa, 1999, Expression of 15-lipoxygenase-1 in human colorectal cancer, Cancer Res, 59, 360 Funk, 2001, Prostaglandins and leukotrienes: advances in eicosanoid biology, Science, 294, 1871, 10.1126/science.294.5548.1871 Larre, 2008, PGE2 and LTB4 tissue levels in benign and cancerous prostates, Prostaglandins Other Lipid Mediat, 87, 14, 10.1016/j.prostaglandins.2008.05.001 Bachi, 2009, Leukotriene B4 creates a favorable microenvironment for murine melanoma growth, Mol Cancer Res, 7, 1417, 10.1158/1541-7786.MCR-09-0038 Hennig, 2004, Effect of LY293111 in combination with gemcitabine in colonic cancer, Cancer Lett, 210, 41, 10.1016/j.canlet.2004.02.023 Hennig, 2005, LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice, Neoplasia, 7, 417, 10.1593/neo.04559 Adrian, 2008, The role of PPARgamma Receptors and Leukotriene B(4) Receptors in mediating the effects of LY293111 in Pancreatic Cancer 2008, PPAR Res, 827096 Zhou, 2011, Circulating LTD4 in patients with hepatocellular carcinoma, Tumour Biol, 32, 139, 10.1007/s13277-010-0107-8 Ghosh, 1997, Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase, Biochem Biophys Res Commun, 235, 418, 10.1006/bbrc.1997.6799 Myers, 1999, Lipoxygenase inhibition in prostate cancer, Eur Urol, 35, 395, 10.1159/000019915 Ghosh, 1998, Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells, Proc Natl Acad Sci USA, 95, 13182, 10.1073/pnas.95.22.13182 Tang, 1999, 12(S)-HETE in cancer metastasis, Adv Exp Med Biol, 447, 181, 10.1007/978-1-4615-4861-4_17 Honn, 1994, 12-lipoxygenases and 12(S)-HETE: role in cancer metastasis, Cancer Metastasis Rev, 13, 365, 10.1007/BF00666105 Moreno, 2009, New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development, Biochem Pharmacol, 77, 1, 10.1016/j.bcp.2008.07.033 Kim, 2005, An antitumorigenic role for murine 8S-lipoxygenase in skin carcinogenesis, Oncogene, 24, 1174, 10.1038/sj.onc.1208269 Schweiger, 2007, Inducible expression of 15-lipoxygenase-2 and 8-lipoxygenase inhibits cell growth via common signaling pathways, J Lipid Res, 48, 553, 10.1194/jlr.M600311-JLR200 Godson, 2000, Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages, J Immunol, 164, 1663, 10.4049/jimmunol.164.4.1663 Rao, 2007, Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton, J Pharmacol Exp Ther, 321, 1154, 10.1124/jpet.106.115436 Schmelzer, 2005, Soluble epoxide hydrolase is a therapeutic target for acute inflammation, Proc Natl Acad Sci USA, 102, 9772, 10.1073/pnas.0503279102 Schottelius, 2002, An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile, J Immunol, 169, 7063, 10.4049/jimmunol.169.12.7063 Zhou, 2009, Lipoxin A(4) inhibited hepatocyte growth factor-induced invasion of human hepatoma cells, Hepatol Res, 39, 921, 10.1111/j.1872-034X.2009.00520.x Chen, 2010, Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis, Mol Cancer Ther, 9, 2164, 10.1158/1535-7163.MCT-10-0173 Decker, 2009, Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells, Am J Physiol Cell Physiol, 296, C1420, 10.1152/ajpcell.00380.2008 Fisslthaler, 1999, Cytochrome P450 2C is an EDHF synthase in coronary arteries, Nature, 401, 493, 10.1038/46816 Kaspera, 2009, Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology, Expert Opin Drug Metab Toxicol, 5, 757, 10.1517/17425250902932923 Zeldin, 1993, Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase, J Biol Chem, 268, 6402, 10.1016/S0021-9258(18)53266-X Yu, 2000, Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids, Circ Res, 87, 992, 10.1161/01.RES.87.11.992 Guo, 2008, Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo, J Pharmacol Exp Ther, 327, 10, 10.1124/jpet.108.140889 Guo, 2005, Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A, J Pharmacol Exp Ther, 315, 526, 10.1124/jpet.105.088567 Guo, 2006, 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N′-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A, J Pharmacol Exp Ther, 317, 97, 10.1124/jpet.105.097782 Alexanian, 2009, Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth, Anticancer Res, 29, 3819 Yu, 2010, Cytochrome P450 omega-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer, Cancer Chemother Pharmacol Nithipatikom, 2006, Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases, Cancer Lett, 233, 219, 10.1016/j.canlet.2005.03.025 Schmelzer, 2006, Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors, Proc Natl Acad Sci USA, 103, 13646, 10.1073/pnas.0605908103 Norwood, 2010, Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis, Am J Transl Res, 2, 447 Pozzi, 2005, Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids, J Biol Chem, 280, 27138, 10.1074/jbc.M501730200 Folkman, 1990, What is the evidence that tumors are angiogenesis-dependent?, J Natl Cancer Inst, 82, 4, 10.1093/jnci/82.1.4 Yang, 2003, Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma, Oncol Rep, 10, 271 Roques, 1991, Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione S-transferase and UDP-glucuronosyltransferases in H5-6 hepatoma cells, Gen Pharmacol, 22, 677, 10.1016/0306-3623(91)90077-J Enayetallah, 2006, Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms, J Mol Histol, 37, 133, 10.1007/s10735-006-9050-9 Kim, 2010, Western-style diets induce macrophage infiltration and contribute to colitis-associated carcinogenesis, J Gastroenterol Hepatol, 25, 1785, 10.1111/j.1440-1746.2010.06332.x Jia, 2008, Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice, Cancer Res, 68, 3985, 10.1158/0008-5472.CAN-07-6251 Lou, 2011, Effects of high fat diets rich in either omega-3 or omega-6 fatty acids on UVB-induced skin carcinogenesis in SKH-1 mice, Carcinogenesis, 10.1093/carcin/bgr074 Weylandt, 2011, Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-{alpha}, Carcinogenesis, 10.1093/carcin/bgr049 Gleissman, 2010, Omega-3 fatty acids in cancer, the protectors of good and the killers of evil?, Exp Cell Res, 10.1016/j.yexcr.2010.02.039 Cockbain, 2011, Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer, Gut, 10.1136/gut.2010.233718 Serhan, 2010, Novel lipid mediators and resolution mechanisms in acute inflammation to resolve or not?, Am J Pathol, 10.2353/ajpath.2010.100322 Levy, 2010, Resolvins and protectins: natural pharmacophores for resolution biology, Prostaglandins Leukot Essent Fatty Acids, 82, 327, 10.1016/j.plefa.2010.02.003 Serhan, 2004, Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers, Lipids, 39, 1125, 10.1007/s11745-004-1339-7 Arita, 2005, The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids, Biochem Biophys Res Commun, 338, 149, 10.1016/j.bbrc.2005.07.181 Serhan, 2008, Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators, Nat Rev Immunol, 8, 349, 10.1038/nri2294 Gleissman, 2010, Omega-3 fatty acids in cancer, the protectors of good and the killers of evil?, Exp Cell Res, 316, 1365, 10.1016/j.yexcr.2010.02.039 Narayanan, 2005, A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors, Int J Oncol, 26, 785 Chiu, 2005, Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells, Biomed Pharmacother, 59, S293, 10.1016/S0753-3322(05)80049-6 Gleissman, 2010, Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates, FASEB J, 24, 906, 10.1096/fj.09-137919